Organon Dermatology to present new Phase 3 analysis of VTAMA eczema data at the Society for Pediatric Dermatology annual meeting on July 23, 2026.

Opposition to AI infrastructure is crystallizing into a political force — the likes of which this province has seen before.

Strategic initiative to accelerate practical quantum computing through cross-platform execution to reach fault-tolerant performance ...

Security tooling is not written in a single language. Python powers most automation. C sits at the exploit layer. PowerShell ...

Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer’s disease and provided evidence-based support for ...

The Sports Analytics Research Group employs quantitative analysis to give teams the hard numbers they need to perform better ...

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a ...

Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment ...

Oklo Inc. (NYSE: OKLO) ("Oklo"), an advanced nuclear technology company, today announced that the U.S. Department of Energy ...

The inaugural season of the Gomezgil Yaspik Data Science Laboratory marks the beginning of a new chapter for for Bowdoin.

A new law taking effect Wednesday expands a Yale pilot program that uses psilocybin with structured therapy to treat ...